Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine–metabolic and ultrasonographic differences

References

• Reis RM, Foss MC, Moura MD, et al. Insulin secretion in obese and non-obese women with polycystic ovary syndrome and its relationship with hyperandrogenism. Gynecol Endocrinol 1995;9: 45–50
   PubMedGoogle Scholar
• Sutterlin M, Steck T. Sensitivity of plasma insulin levels in obese and non-obese women with functional hyperandrogenism. Gynecol End ocrinol 1995;9:37–44
   PubMedGoogle Scholar
• Goldzieher JW, Axelrod IR. Clinical and bio-chemical features of polycystic ovarian disease. Fertil Steril 1963;14:631–6
   PubMed Web of Science ®Google Scholar
• Lobo RA. Hirsutism in polycystic ovary syndrome: current concepts. Clin Obstet Gynecol 1991;34: 817–26
   PubMed Web of Science ®Google Scholar
• Aono T, Miyazaki M, Miyake A, et al. Responses of serum gonadotrophins to LH-releasing hormone and oestrogens in Japanese women with polycystic ovaries. Acta Endocrinol (Copenh) 1977;85:840–8
   PubMedGoogle Scholar
• Conway GS, Honour JW, Jacobs HS. Hetero-geneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol 1989;30: 459–70
   Google Scholar
• Goodman GJ. Management of post-acne scarring. Am J Clin Dermatol 2000;1:3–17
   PubMedGoogle Scholar
• Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol 1999; 41:577–80
   PubMed Web of Science ®Google Scholar
• Slayden SM, Moran C, Sams WM, et al. Hyper-androgenemia in patients presenting acne. Fertil Steril 2001;75:889–92
   PubMed Web of Science ®Google Scholar
• Schmidt JB, Sp ona J, Huber J. Androgen receptor in hirsutism and acne. Gynecol Obstet Invest 1986;22:206–11
   PubMed Web of Science ®Google Scholar
• McKenna TJ. Variable androgen sensitivity in rela-tionship to hirsutism and acne. Clin Endocrinol 1993;39:547–9
   PubMed Web of Science ®Google Scholar
• George FW, Russel DW, Wilson JD. Feed-forward control of prostatic growth: dihydro-testosterone induces expression of its own biosynthetic enzyme, steroid 5a-reductase. Proc Nat/ Acad Sci USA 1991;88: 8044–7
   Google Scholar
• Jahanfar S, Eden JA, Warren P, et al. A twin study of polycystic ovary syndrome. Fertil Steril 1995;63:478–86
   PubMed Web of Science ®Google Scholar
• Serafini PC, Lobo RA. Increased 5a-reductase activity in idiopathic hirsutism. Fertil Steril 1985; 43:74–8
   PubMed Web of Science ®Google Scholar
• Serafini PC, Ablan F, Lobo RA. 5a-Reductase activity in the genital skin o f hirsute women. J Clin Endocrinol Metab 1985;60: 349–55
   Google Scholar
• Horton R. Dihydrotestosterone is a peripheral paracrine hormone. J Androl 1992;13:23–6
   PubMedGoogle Scholar
• Greep N, Hoopes M, Horton R. Androstanediol glucuronide plasma clearance and production rates in normal and hirsute women. J Clin Endocrinol Metab 1986;62:22–7
   Google Scholar
• Falsetti L, Rosina B, De Fusco D. Serum levels of 3a-androstanediol glucuronide in hirsute and non-hirsute women. Eur J Endocrinol 1998;138: 101–9
   Google Scholar
• Duffy DM, Legro RS, Chang L, et al. Metabolism of dihydrotestosterone to 5a-androstane and 3a, 1713-diol glucuronide is greater in the peripheral compartment than in the splanchnic compartment. Fertil Steril 1995;64:736–9
   PubMedGoogle Scholar
• Carrnina E, Stanczyk FZ, Matteri RK, et al. Serum androsterone conjugates differentiate between acne and hirsutism in hyperandrogenic women. Fertil Steril 1991;55:872–6
   PubMedGoogle Scholar
• Toscano V, Balducci R, Bianchi P, et al. Two different pathogenetic mechanisms may play a role in acne and hirsutism. Clin Endocrinol (Oxj) 1993; 39:551–6
   PubMedGoogle Scholar
• Marynick SP, Chakmakijan ZH, McCafree DL, et al. Androgen excess in cystic acne. N Engl J Med 1983;308:981–4
   PubMed Web of Science ®Google Scholar
• Lobo RA. Hirsutism, alopecia and acne. In Becker KL, ed. Principles, and Practice of Endocrinology and Metabolism. Philadelphia: Lippincott, 1990:834–56
   Google Scholar
• Ebling FJ, Ebling E, McCaffery V, et al. The response of the sebaceous glands of the hypo-physectomized castrated male rat to 5a-andro-stanedione and 5a-androstane-3I3, 1713-diol. J Endocrinol 1973;60:183–5
   Google Scholar
• Ebling FJ, Ebling E, McCaffey V. The response of the sebaceous glands of the hypophysectomized castrated male rat to 5a-dihydrotestosterone, androstenedione, dehydroepiandrosterone and androsterone. J Endocrinol 1971;45: 245–59
   Google Scholar
• Strauss JS, Po chi PE, Dowming DT. The sebaceous glands: twenty-five years of progress. J Invest Dermatol 1976;67:90–5
   PubMedGoogle Scholar
• Imperato-McGinley J, Gautier T, Cai L, et al. The androgen control of sebum production. Study of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 1993;76:524–8
   Google Scholar
• Andersson S, Berman DM, Jenkins EP, et al. Deletion of steroid 5a-reductase 2 genes in male pseudo hermaphro ditism. Nature (London) 1991; 354:159–61
   PubMed Web of Science ®Google Scholar
• Wilson JD, Griffin JE, Russel DW. Steroid 5a-reductase deficiency. Endocr Rev 1993;14: 577–93
   Google Scholar
• Harris G, Azzolina B, Baginsky W, et al. Identifica-tion and selective inhibition of an isozyme of steroid 5a-reductase in human scalp. Proc Nat/ Acad Sci USA 1992;89:10787–91
   PubMed Web of Science ®Google Scholar
• Mestayer CH, Berthaut I, Portois MC, et al. Pre-dominant expression of 5a-reductase type 1 in pubic skin from normal subjects and hirsute patients . J Clin Endocrinol Metab 1996;81:1989–93
   PubMed Web of Science ®Google Scholar
• Thigpen AE, Silver RI, Guileyardo JM, et al. Tissue distribution and ontogeny of steroid 5a-reductase isozyme expression. J Clin Invest 1993;92:903–10
   PubMed Web of Science ®Google Scholar
• Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–8
   PubMed Web of Science ®Google Scholar
• Rosenfield RL. Pilosebaceous physiology in rela-tion to hirsutism and acne. J Clin Endocrinol Metab 1986;15:341–62
   Google Scholar
• Orsini LF, Rizzo N, Calderoni P. Ultrasound monitoring of ovarian follicular development: a comparison of real time and static scanning techniques. J Clin Ultrasound 1993;11:207–13
   Google Scholar
• Adams J, Franks S, Polson DW, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985;2:1375–8
   PubMed Web of Science ®Google Scholar
• National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039–57
   PubMed Web of Science ®Google Scholar
• Falsetti L, Gambera A, Andrico S, et al. Insulin resistance and lipid metabolism in polycystic ovary syndrome. In Genazzani AR, Artini PG, Petraglia F, eds. Recent Research in Gynecological Endocrinology. Carnforth, UK: Parthenon Publishing, 2000:27–30
   Google Scholar
• Rosenfield RL, Barnes RB, Cara JF, et al. Dys-regulation of cytochrome P450c17a as the cause of polycystic ovary syndrome. Fertil Steril 1990;53: 785–91
   PubMed Web of Science ®Google Scholar
• Rodin A, Thakkar H, Taylor N, et al. Hyperandro-genism in polycystic ovary syndrome: evidence of dysregulation of 11I3-hydroxysteroid dehydro-genase. N Engl J Med 1994;17:460–5
   Google Scholar
• Barnes RB. Pathophysiology of ovarian steroid secretion in polycystic ovary syndrome. Semin Reprod Endocrinol 1997;15:159–68
   PubMedGoogle Scholar
• Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 activity and serum androgens. J Clin Endocrinol Metab 1997;82:4075–9
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ. Decreases in ovarian P450c17 activity and serum free testosterone after reduction in insulin secretion in women with poly-cystic ovary syndrome. N Engl J Med 1996;335: 617–23
   PubMed Web of Science ®Google Scholar
• Kondoh Y, Uemura T, Ishikawa M, et al. Classifi-cation of polycystic ovary syndrome into three types according to response to human corticotropin-releasing hormone. Fertil Steril 1999; 72:15–20
   PubMed Web of Science ®Google Scholar
• Lanzone A, Fulghesu AM, Guido M, et al. Differ-ential androgens response to adrenocorticotropic hormone stimulation in polycystic ovarian syndrome: relationship with insulin secretion. Fertil Steril 1992;58:296–301
   PubMed Web of Science ®Google Scholar
• Ke WX, Shan GQ, Hua SY. Different responses of insulin, C-peptide, and testoterone to an oral glucose tolerance test in two groups of wo men with polycystic ovarian syndrome. Acta Obstet Gynecol Scand 1996;75:166–9
   Google Scholar
• Mahabeer S, Jialal I, Norman RJ, et al. Insulin and C-peptide secretion in non obese patients with polycystic ovarian disease. Horm Metab Res 1989; 21:502–6
   PubMed Web of Science ®Google Scholar
• Morales AJ, Laughlin GA, Butzo WT, et al. Insulin, somatotropic and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996;81:2854–64
   PubMed Web of Science ®Google Scholar
• Arroyo A, Laughlin GA, Morales AJ, et al. Inappro-priate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab 1997;82:3728–33
   PubMed Web of Science ®Google Scholar
• Homburg R, Pariente C, Lunenfel B, et al. Role of insulin-like growth factor-1 (IGF-I) and IGF binding protein-1 (IGFBP-1) in the pathogenesis of polycystic ovary syndrome. Hum Reprod 1992; 7:1379–83
   PubMed Web of Science ®Google Scholar
• Conway GS, Jacobs HS, Holly JMP, et al. Effects of luteinizing hormone, insulin, insulin-like growth factor-binding protein in patients with polycystic ovary syndrome. Hum Reprod 1998;13:146–53
   Google Scholar
• Suikkari AM, Ruutianen K, Erkkola R, et al. Low levels of low molecular weight insulin-like growth factor-binding protein in patients with polycystic ovary syndrome. Hum Reprod 1989;4:136–9
   PubMed Web of Science ®Google Scholar
• Duleba AJ, Spaczynski RZ, Olive DL. Insulin and insulin-like growth factor I stimulate the prolifera-tion of human ovarian theca—interstitial cells. Fertil Steril 1998;69:335–40
   Google Scholar
• Danilenko DM, Ring BD, Pierce GF. Growth factors and cytokines in hair follicle development and cycling: recent insights from animal models and the potentials for clinical therapy. Mol Med Today 1996;2:460–7
   Google Scholar
• Hembree JR, Harmon CS, Nevins TD, et al. Regulation of human dermal papilla cell produc-tion ofinsulin-like growth factor binding protein-3 by retinoic acid, glucocorticoids, and insulin-like growth factor-1. J Cell Physiol 1996;167:556–61
   PubMed Web of Science ®Google Scholar
• Paulson RJ, Serafini PC, Catalino JA, et al. Measurements of 3a, 17I3-androstanediolglucuro-nide in serum and urine and the correlation with skin 5a-reductase activity. Fertil Steril 1986;46: 222–6
   PubMed Web of Science ®Google Scholar
• Falsetti L, Gambera A, Tisi GC. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on the endocrine, clinical and ultrasono-graphic profile in polycystic ovarian syndrome. Hum Reprod 2001;16:36–42
   Google Scholar
• Falsetti L, Gambera A, Platto C, et al. Management of hirsutism. Am J Clin Dermatol 2000;1:89-99 levels of androgens receptors than those from non-balding scalp. J Endocrinol 1998;156: 59–65
   Google Scholar
• Falsetti L, Gambera A, Legrenzi L, et al. Compari-son of finasteride versus flutamide in the treatment of hirsutism. Eurj Endocrinol 1999;141:361–7
   PubMed Web of Science ®Google Scholar
• Hibberts NA, Howell AE, Randall VA. Balding hair follicle dermal papilla cells contain higher
   Google Scholar